The FDA has approved two cell-based gene therapies for sickle cell disease, Casgevy from CRISPR/Vertex and Lyfgenia from Bluebird Bio, which are the first treatments available to individuals with SCD in the United States.
Author Archives: Clayton Gutzmore
Clayton Gutzmore is a freelance journalist in South Florida. He published stories in several news outlets including The Miami Times, 91.3 WLRN, The Atlanta Voice, BET, and Variety Magazine. Gutzmore graduated from Florida International University. During undergrad, he served on the board of the local chapter of the National Association of Black Journalists.
Gutzmore is 2021 Dori Maynard Diversity Fellow for The Society of Professional Journalists. He is a member of the Sigma Alpha chapter of Omega Psi Phi Fraternity Inc.
